Efficient prioritization of CRISPR screen hits by accounting for targeting efficiency of guide RNA.

Abstract excerpt

BACKGROUND: CRISPR-based screens are revolutionizing drug discovery as tools to identify genes whose ablation induces a phenotype of interest. For instance, CRISPR-Cas9 screening has been successfully used to identify novel therapeutic targets in cancer where disruption of genes leads to decreased viability of malignant cells. However, low-activity guide RNAs may give rise to variable changes in phenotype,...

Topics

Join the communities discussing this publication.

• Cell Line
• CRISPR-Cas Systems
• Mutation
• RNA
• Vemurafenib